Belite Bio Inc (BLTE) Hedge Fund Ownership (Q1 2026)

Q: Is it too late to buy Belite Bio Inc (BLTE) following the 2026 Q2 hedge fund 13F filings?

As of today, BLTE has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), BLTE gained +5.7% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Belite Bio Inc (BLTE)

74 + Investors. Track Smart Money conviction in BLTE. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — BLTE

Based on 74 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added BLTE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

74 hedge funds hold BLTE right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +311% more funds vs a year ago

fund count last 6Q

+56 new funds entered over the past year (+311% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 60% buying

55 buying36 selling

Last quarter: 55 funds were net buyers (28 opened a brand new position + 27 added to an existing one). Only 36 were sellers (14 trimmed + 22 sold completely). A clear majority buying is a strong confirmation signal.

⚠️

Fewer new buyers each quarter (-11 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 6 → 16 → 39 → 28. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 74% entered in last year

■ 8% conviction (2yr+) ■ 18% medium ■ 74% new

Only 6 funds (8%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

🚀

Acceleration phase — new buyers rushing in

7 → 6 → 16 → 39 → 28 new funds/Q

New funds entering each quarter: 6 → 16 → 39 → 28. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.

🌱

Early stage — 77% of holders entered in last year

■ 15% veterans ■ 8% 1-2yr ■ 77% new

Of 74 current holders: 57 (77%) entered in the past year, only 11 (15%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

✅

Strong quality — 21% AUM from major funds

21% from top-100 AUM funds

21 of 74 holders rank in the top 100 by AUM, accounting for 21% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

6.9

out of 10

Moderate Exit Risk

Exit risk score 6.9/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	74	68	8.82%
13F Shares	9M	7M	27.39%
Total Value	$1.36B	$1.15B	18.14%
New Positions	28	39	-11
Increased Positions	27	17	+10
Closed Positions	22	5	+17
Reduced Positions	14	10	+4
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

8.82%

13F Shares

27.39%

Total Value

$1.36B

$1.15B

18.14%

New Positions

-11

Increased Positions

+10

Closed Positions

+17

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q2)

74 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in BLTE. Verified SEC 13F-HR filings.

QUARTER:

2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 BLTE holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Darwin Global Management, Ltd.	12.14%	3,077,219	$456.6M
2	Paradigm Biocapital Advisors LP	3.55%	1,232,877	$189.8M
3	Patient Square Capital LP	2.62%	110,000	$16.9M
4	Balance Capital Partners L.P.	2.49%	22,500	$3.5M
5	Verdad Advisers, LP	2.03%	13,758	$2.1M
6	Logos Global Management LP	1.66%	250,000	$38.5M
7	MPM BioImpact LLC	1.29%	137,208	$21.1M
8	Affinity Asset Advisors, LLC	1.15%	165,000	$25.4M
9	Rtw Investments, LP	0.94%	715,332	$110.2M
10	Eventide Asset Management, LLC	0.80%	390,829	$60.2M
11	Artia Global Partners LP	0.71%	24,989	$3.8M
12	Deerfield Management Company, L.P.	0.57%	357,199	$55.0M
13	Maverick Capital Ltd	0.54%	396,311	$61.0M
14	PFM Health Sciences, LP	0.46%	34,803	$5.4M
15	HighVista Strategies LLC	0.34%	9,554	$1.5M
16	Soleus Capital Management, L.P.	0.27%	50,524	$7.8M
17	SmartHarvest Portfolios, LLC	0.22%	4,359	$671K
18	High Net Worth Advisory Group LLC	0.11%	3,500	$539K
19	R Squared Ltd	0.11%	1,338	$206K
20	Holocene Advisors, LP	0.09%	251,035	$38.7M
21	Virtus Investment Advisers, LLC	0.08%	2,369	$365K
22	Capricorn Fund Managers Ltd	0.08%	6,400	$986K
23	Arrowpoint Investment Partners (Singapore) Pte. Ltd.	0.07%	2,008	$309K
24	Trexquant Investment LP	0.04%	49,516	$7.6M
25	Bayforest Capital Ltd	0.04%	307	$47K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Belite Bio Inc (BLTE)

What does the Smart Money Trend signal show for BLTE?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added BLTE than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for BLTE?

More buyers than sellers — 60% buying: Last quarter: 55 funds were net buyers (28 opened a brand new position + 27 added to an existing one). Only 36 were sellers (14 trimmed + 22 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for BLTE holders?

Strong quality — 21% AUM from major funds: 21 of 74 holders rank in the top 100 by AUM, accounting for 21% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held BLTE?

Mostly new holders — 74% entered in last year: Only 6 funds (8%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Belite Bio Inc (BLTE) following the 2026 Q2 hedge fund 13F filings?

As of today, BLTE has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), BLTE has gained +5.7% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Belite Bio Inc (BLTE)

Smart Money Signals — BLTE

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +311% more funds vs a year ago

More buyers than sellers — 60% buying

Fewer new buyers each quarter (-11 vs last Q)

Mostly new holders — 74% entered in last year

Acceleration phase — new buyers rushing in

Early stage — 77% of holders entered in last year

Strong quality — 21% AUM from major funds

Institutional Sentiment Summary — BLTE

Hedge Fund Ownership: BLTE

Market Analysis: BLTE

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: BLTE

Is It Too Late to Buy Belite Bio Inc (BLTE) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: BLTE

Statistics: BLTE

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q2)

Frequently Asked Questions — Belite Bio Inc (BLTE)

Welcome to 13Foresight!